Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology.
Horgan D, Ciliberto G, Conte P, Baldwin D, Seijo L, Montuenga LM, Paz-Ares L, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Capoluongo E, Banerjee S, Riegman P, Kerr K, Horbach B, Büttner R, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Westphalen B, Calvo F, Koeva-Balabanova J, Hall S, Paradiso A, Kalra D, Cobbaert C, Varea Menendez R, Maravic Z, Fotaki V, Bennouna J, Cauchin E, Malats N, Gutiérrez-Ibarluzea I, Gannon B, Mastris K, Bernini C, Gallagher W, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Sarnowska E, Jagielska B, Mee S, Curigliano G. Horgan D, et al. Among authors: buglioni s. Biomed Hub. 2020 Sep 14;5(3):182-223. doi: 10.1159/000511209. eCollection 2020 Sep-Dec. Biomed Hub. 2020. PMID: 33564664 Free PMC article.
Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine.
Horgan D, Ciliberto G, Conte P, Curigliano G, Seijo L, Montuenga LM, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Riegman P, Kerr K, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Koeva-Balabanova J, Paradiso A, Maravic Z, Fotaki V, Malats N, Bernini C, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Jagielska B, Capoluongo E. Horgan D, et al. Among authors: buglioni s. Cancers (Basel). 2021 Feb 2;13(3):583. doi: 10.3390/cancers13030583. Cancers (Basel). 2021. PMID: 33540773 Free PMC article.
[Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.].
Esposito I, Calabria S, Piccinni C, Addesi A, Dondi L, Ronconi G, Pedrini A, Maggioni AP, Curigliano G, Listi A, Righi L, Novello S, Buglioni S, Ciliberto G, Pruneri G, Martini N. Esposito I, et al. Among authors: buglioni s. Recenti Prog Med. 2021 Jun;112(6):419-437. doi: 10.1701/3620.36025. Recenti Prog Med. 2021. PMID: 34128934 Italian.
Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is the only option available.
Ercolani C, Di Benedetto A, Bonomo C, Visca P, Palange A, Assisi D, Forcella D, Terrenato I, Pescarmona E, Ciliberto G, Cecere FL, Cappuzzo F, Buglioni S. Ercolani C, et al. Among authors: buglioni s. J Clin Pathol. 2022 Dec;75(12):844-850. doi: 10.1136/jclinpath-2021-207726. Epub 2021 Aug 16. J Clin Pathol. 2022. PMID: 34400544 Free PMC article.
Pretreated EGFRdel19/BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report.
Orciuolo C, Cappuzzo F, Landi L, Resuli B, Carpano S, Vidiri A, Buglioni S, Mandoj C, Ciliberto G, Minuti G. Orciuolo C, et al. Among authors: buglioni s. JTO Clin Res Rep. 2023 Jun 30;4(8):100545. doi: 10.1016/j.jtocrr.2023.100545. eCollection 2023 Aug. JTO Clin Res Rep. 2023. PMID: 37533438 Free PMC article.
KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
Scalera S, Mazzotta M, Corleone G, Sperati F, Terrenato I, Krasniqi E, Pizzuti L, Barba M, Vici P, Gallo E, Buglioni S, Visca P, Pescarmona E, Marinelli D, De Nicola F, Ciuffreda L, Goeman F, Fanciulli M, Giusti R, Vecchione A, De Maria R, Cappuzzo F, Marchetti P, Ciliberto G, Maugeri-Saccà M. Scalera S, et al. Among authors: buglioni s. J Thorac Oncol. 2021 Dec;16(12):2065-2077. doi: 10.1016/j.jtho.2021.08.010. Epub 2021 Aug 25. J Thorac Oncol. 2021. PMID: 34450259 Free article.
A Real-World Systematic Analysis of Driver Mutations' Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting.
Terrenato I, Ercolani C, Di Benedetto A, Gallo E, Melucci E, Casini B, Rollo F, Palange A, Visca P, Pescarmona E, Melis E, Gallina F, Sacconi A, Cecere FL, Landi L, Cappuzzo F, Ciliberto G, Buglioni S. Terrenato I, et al. Among authors: buglioni s. Cancers (Basel). 2022 Jun 16;14(12):2971. doi: 10.3390/cancers14122971. Cancers (Basel). 2022. PMID: 35740637 Free PMC article.
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma.
Gallina FT, Tajè R, Letizia Cecere F, Forcella D, Landi L, Minuti G, Fusco F, Buglioni S, Visca P, Melis E, Sperduti I, Ciliberto G, Cappuzzo F, Facciolo F. Gallina FT, et al. Among authors: buglioni s. Lung Cancer. 2023 Jun;180:107215. doi: 10.1016/j.lungcan.2023.107215. Epub 2023 Apr 25. Lung Cancer. 2023. PMID: 37126920
91 results